ARTICLE | Product Development

Phase I start marks first for anti-SARS-CoV-2 mAbs, first for AbCellera

June 2, 2020 1:29 AM UTC

A COVID-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I study of Ly-CoV555 is assessing safety, its evaluation in hospitalized COVID-19 patients leaves room for exploratory observations that may hint at efficacy.

Eli Lilly and Co. (NYSE:LLY) announced Monday it had dosed the first patients in the Phase I J2W-MC-PYAA study, a randomized, placebo-controlled trial evaluating safety and PK/PD of Ly-CoV555. Data are due by the end of this month. ...